PDD00017273 is a radiosensitizing PARG) inhibitor with antitumor or activity for the study of epithelial ovaries.

COH34 (1-[(E)-(4-methylphenyl)sulfanyliminomethyl]naphthalen-2-ol) is a selective inhibitor of PARG with an IC50 of 0.37 nM and a Kd of 0.547 μM. COH34 prolongs PARylation at DNA lesions and traps DNA repair factors.

PDD00017272 (34f) is a potent inhibitor of poly(ADP-ribose) glycohydrolase (PARG), exhibiting an EC50 value of 4.8 nM in biochemical assays and 9.2 nM in cellular POM.

Endo-1,4-β-xylanase (Xylanase), a glycoside hydrolase enzyme that degrades arabinoxylan (AX), is commonly utilized in biochemical research. It specifically hydrolyzes the β-xylosidic bonds linking two d-xylopyranosyl residues in a β-(1,4) configuration [1].

COH34 analog 1 is a COH34 oxidation analogue that can be used to synthesize active compounds.

PARG-IN-4 (compound A) is an orally active and cell-membrane permeable PARG inhibitor (EC50=1.9 nM) that inhibits tumour growth in mice with antitumour activity.

pNP-ADPr is a colorimetric substrate used in continuous activity assays for Poly(ADP-ribose) glycohydrolase (PARG) and ADP-ribosyl hydrolase 3 (ARH3), aiding research on poly(ADP-ribose) polymerase (PARP) enzymes.

PARG-IN-7 (Example 38) is a Poly ADP-ribose glycohydrolase (PARG) inhibitor with an IC50 of less than 0.1 μM. It reduces the viability of HCC1806-XRCC1 knockdown (KD) cells, exhibiting an IC50 of less than 1 μM. PARG-IN-7 is applicable in cancer research.

PDD00017238 demonstrates a robust inhibitory effect on Poly(ADP-ribose) Glycohydrolase (PARG), displaying EC50 values of 40 nM in biochemical assay and 55 nM in cell POM assessment.

TFMU-ADPr serves as a versatile substrate for assessing poly(ADP-ribose) glycohydrolase (PARG) activity, enabling direct measurement of total PAR hydrolase activity through the liberation of a fluorophore. Exhibiting exceptional reactivity, generality, stability, and usability, TFMU-ADPr is an effective tool for evaluating small-molecule inhibitors and investigating the regulation of ADP-ribosyl catabolic enzymes in vitro [1].

PARP-1-IN-32 (compound 15) is an inhibitor of poly (ADPribose) polymerase-1 (PARP-1), specifically designed for use in cancer research.

TFMU-ADPr triethylamine, a versatile substrate for evaluating poly(ADP-ribose) glycohydrolase (PARG) activity, enables direct measurement of total PAR hydrolase activity through the liberation of a fluorophore. With outstanding reactivity, generality, stability, and usability, it serves as an essential tool for the in vitro assessment of small-molecule inhibitors and exploration of the regulation of ADP-ribosyl catabolic enzymes [1].

Ethacridine acts as an inhibitor of poly (ADP-ribose) glycohydrolase (PARG) and functions as an activator of transcriptional coactivators. It induces apoptosis in thyroid cancer cells and promotes the differentiation of thyroid follicular cells.

JA2131, a small molecular inhibitor targeting Poly(ADP-ribose) Glycohydrolase (PARG), has an IC50 value of 0.4 μM, modulates DNA damage responses, induces replication fork stalling, and leads to cancer cell death.

PDD00031705 is a benzimidazolone core, cell-inactive Poly (ADP-ribose) glycohydrolase (PARG) inhibitor.

pNP-ADPr disodium serves as a colorimetric substrate in the inaugural continuous assays of Poly(ADP-ribose) glycohydrolase (PARG) and ADP-ribosyl hydrolase 3 (ARH3) activities. It also facilitates research into poly(ADP-ribose)polymerase (PARP) enzymes [1] [2].

PARG-IN-6 (Compound 2) is an orally bioavailable PARG inhibitor with an IC50 of 0.3 nM. It exhibits significant anticancer activity against cancer cells, with an IC50 of 0.0368 μM for HCC1395 cells. PARG-IN-6 shows potential for research in colon cancer, appendiceal cancer, and pancreatic cancer.